Rooted in Science

Bud & Mary’s honest formulation and production process are built on a solid foundation that meets all high-quality cannabis standards and cGMP (current Good Manufacturing Practices), and GACP (Good Agricultural Collection Practices) requirements. With support from our in-house cannabis research team, we understand that a reputable formulation and the efficacy and safety of finished products are of the utmost importance.

AT OUR CORE

High Quality Plant Precision

Our core values guide every decision we make at Bud & Mary’s. From seed to your home, our products are made with the perfect balance of expertise and care, resulting in cannabis products you can be proud to consume.

DEA Licensed

Bud & Mary’s is the first to receive a Colorado Cannabis Research License in the United States for cannabis clinical trials.

cGMP Facility

Bud & Mary’s is the first pharmaceutical-grade cannabis company to obtain a cGMP and cGACP (current Good Agricultural and Collection Practices) certification in the United States.

small group pilot study

How Bud & Mary’s Will Investigate the Efficacy of Cannabis in Dementia Patients

Our expertise and innovative testing will allow us to conduct a clinical trial with a 30-patient randomized and placebo-controlled pilot study to research the symptomatic improvements proper dosing of our patented Brain Health Formula has in dementia patients.

World-class research partners

We’ve teamed up with industry experts, including: a neurologist MD, a neuro-inflammatory blood biomarker analysis company, and a brain scan company.

Innovative testing

This study is the first randomized placebo-controlled clinical trial to use and dispense purposefully formulated cannabis-derived medicines.

People first values

Bud & Mary’s conducts this research in effort to correlate symptomatic improvements with psychological benefits.

Why is this important?

Alzheimer’s Disease is the most common form of Dementia and is the 6th leading cause of death in the U.S. There is no known cure for dementia and current support therapies are of limited benefit.

1 in 3

One-third of seniors die with some form of Dementia.

46M

Over 46 million people worldwide have Alzheimer’s Disease. This number is projected to increase to 131 million by 2050.

20y

Dementia symptoms can start up to 20 years after the disease onset making prevention and early detection essential.

$818B

Worldwide cost of Alzheimer’s Disease: $818 billion per year.

Symptoms of Alzheimer's Disease Include:

Memory loss
Personality changes
Behavioral problems
Mood changes
Difficulty solving problems
Sleep disturbances

Good Manufacturing Practices

Formulating the future of Cannabis

Bud & Mary’s is a fully integrated cannabis company with a pharmaceutical approach to cannabis. Led by Dr. Duncan Mackie PhD, Director of Pharmacology & Experimental Therapeutics.

Current Cannabis Research Studies

Hypothesis:

Our specially formulated oral gel will improve sleep measures such as Total sleep time (TST), Sleep onset latency (SOL), Saturated Oxygen (SpO2), and outcomes of the Sleep Quality Scale (SQS).

We are conducting the FIRST pilot clinical trial involving our patented oral gel to investigate the effects of cannabinoids on sleep disturbances in individuals 50 years of age and older.

Cannabis and Alzheimer’s

This study aims to isolate unique cannabinoids to evaluate their potential in treating Alzheimer’s disease. By targeting immune cells in their various states, the research hypothesizes that cannabinoids may reduce inflammation in the central nervous system to pave the way for cannabis-derived therapeutics to treat inflammatory neurological disorders.

LABeL

This study evaluates the accuracy of cannabis product label claims versus actual cannabinoid potency in Colorado’s retail market, analyzing over 300 products across categories such as flower, edibles, and concentrates. Conducted by Bud & Mary’s and the University of Colorado Boulder, the project uses independent testing to identify discrepancies, including potential biases in state-licensed laboratories, and assesses microbial contamination in later phases. As the first systematic review of its kind, the findings aim to improve cannabis testing policies, ensure accurate labeling and enhance public health outcomes, with results being shared with policymakers and published in a peer-reviewed journal.

Edible Roulette

The goal of this project is to establish standardized testing methods for cannabis edibles, addressing inconsistencies in potency measurements across products like chocolate and gummies. A collaboration between Bud & Mary’s and the University of Colorado Boulder, the study validates compliant methods to ensure consistency and accuracy in product labeling, improving consumer safety and confidence in dosing. It is the first to systematically analyze edible matrices with extensive solvent panels and recovery methods, with findings intended to guide industry and regulatory standards.

Cannabis and Sleep Trial Clinical Trial This pilot study will examine the effects of a patented cannabinoid- based therapeutic intradermal gel designed to improve sleep among individuals over 50 with diagnosed sleep disturbances. Participants will use the gel daily for 21 days, tracking sleep, pain, and related symptoms to assess the therapeutic potential of CBD for sleep improvement. The study will address a critical gap in research on CBD’s efficacy for older adults, particularly its role in managing sleep disturbances often linked to chronic pain.

Behind Our Cannabis Research Studies

Dr. Duncan Mackie PhD

Director of Pharmacology & Experimental Therapeutics

Duncan I. Mackie, PhD, is the Director of Pharmacology and Experimental Therapeutics at Bud & Mary’s, where he leverages his expertise in drug discovery, cellular and molecular biology, and G-protein-coupled receptors (GPCRs) pharmacology to explore the therapeutic potential of cannabinoids. His work focuses on their interactions with the endocannabinoid system, identifying novel drug targets, and investigating their implications for treating various medical conditions.